Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Original Invest

6 Oct 2006 16:28

AIM06 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: ORIGINAL INVESTMENTS PLC (TO BE RENAMED VIALOGY PLC ON ADMISSION) COMPANY ADDRESS: ASHCOME COURTWOOLSACK WAYGODALMINGSURREY COMPANY POSTCODE: GU7 1LQ COUNTRY OF INCORPORATION: UK COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging their priorexpertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed a technology toseparate the background 'noise' that envelops weak signals called Quantum Resonance Interferometry (QRI), which has thepotential to be adapted to a wide range of measurement, instrumentation and other applications. The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able todetect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square) background noise. Thetechnology was the subject of further development work undertaken in the mass spectrometry industry. Other developmentactivities were carried out in the areas of sensor data processing and transference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be of considerablebenefit in a number of industrial areas and a planned programme of commercialisation has commenced. Discussions at bothdevelopment and commercial levels are being held with a number of international companies and national authorities toverify the suitability of incorporating the ViaLogy technology into existing and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 403,256,437 ORDINARY SHARES OF 1P EACH CAPITAL TO BE RAISED ON ADMISSION: NIL FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: DIRECTORS: JAMES DERRICK SLATER, CHAIRMAN (TO RESIGN ON ADMISSION) TERENCE BOND, MANAGING DIRECTOR AND DEPUTY CHAIRMAN (TO BECOME EXECUTIVE CHAIRMAN ON ADMISSION) DR RICHARD PETER DIXEY, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) JULIAN GEORGE VIGGARS, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) PROPOSED DIRECTORS: MICHAEL WOODS KELLY, PROPOSED CHIEF EXECUTIVE OFFICER DR. SANDEEP GULATI, PROPOSED CHIEF TECHNICAL OFFICER GEORGE REHM, PROPOSED NON-EXECUTIVE DIRECTOR DR. ROBERT WILLIAM DEAN, PROPOSED NON-EXECUTIVE DIRECTOR PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Existing Following AdmissionDirector Number of Percentage of Number of Percentage of Ordinary Shares issued ordinary Ordinary Shares issued ordinary share capital (%) share capital (%) James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5Christopher Slater 12,585,000 4.0 12,585,000 3.1Atlas Capital S.A. 17,700,000 5.7 17,700,000 4.4Dr. John Broome 12,500,000 5.3 13,316,542 3.3Aeris Holdings AG Nil Nil 60,883,923 15.1 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: NONE ANTICIPATED ACCOUNTING REFERENCE DATE: 31 MARCH EXPECTED ADMISSION DATE: 30 OCTOBER 2006 NAME AND ADDRESS OF NOMINATED ADVISER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL NAME AND ADDRESS OF BROKER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL THE ADMISSION DOCUMENT CONTAINS FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES. DATE OF NOTIFICATION: 6 OCTOBER 2006 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.